References
- GradisharWJAlbumin-bound nanoparticle paclitaxelClin Adv Hematol Oncol20053534834916167008
- LeeMKLimSJKimCKPreparation, characterization and in vitro cytotoxicity of paclitaxel-loaded sterically stabilized solid lipid nanoparticlesBiomaterials200728122137214617257668
- DamascelliBCantùGMattavelliFIntra-arterial chemotherapy with polyoxyethylated castor oil free paclitaxel, incorporated in albumin nanoparticles (ABI-007): Phase II study of patients with squamous cell carcinoma of the head and neck and anal canal: preliminary evidence of clinical activityCancer200192102592260211745194
- KeYYeKGrossniklausHEArcherDRNoscapine inhibits tumor growth with little toxicity to normal tissues or inhibition of immune responsesCancer Immunol Immunother2000494–521722510941904
- AnejaRDhimanNIdnaniJPreclinical pharmacokinetics and bioavailability of noscapine, a tubulin-binding anticancer agentCancer Chemother Pharmacol200760683183917285314
- HiserLHerringtonBLobertSEffect of noscapine and vincristine combination on demyelination and cell proliferation in vitroLeuk Lymphoma20084981603160918766974
- JacksonTChouguleMBIchiteNPatlollaRRSinghMAntitumor activity of noscapine in human non-small cell lung cancer xenograft modelCancer Chemother Pharmacol200863111712618338172
- DahlstromBMellstrandTLofdahlCJohanssonMPharmacokinetic properties of noscapineEur J Clin Pharmacol19822265355397128665
- KarlssonMODahlströmBEckernäsSÅJohanssonMATufvesson Alm A. Pharmacokinetics of oral noscapineEur J Clin Pharmacol19903932752792257866
- WinterCAFlatakerLToxicity studies on noscapineToxicol Appl Pharmacol1961319610613785912
- NewcombEWLukyanovYSmirnovaISchneeTZagzagDNoscapine induces apoptosis in human glioma cells by an apoptosis-inducing factor-dependent pathwayAnticancer Drugs200819655356318525314
- AnejaRVangapanduSNLopusMSynthesis of microtubule-interfering halogenated noscapine analogs that perturb mitosis in cancer cells followed by cell deathBiochem Pharmacol200672441542616780803
- AnejaRZhouJZhouBChandraRJoshiHCTreatment of hormone-refractory breast cancer: apoptosis and regression of human tumors implanted in miceMol Cancer Ther2006592366237716985071
- AnejaRVangapanduSNLopusMChandraRPandaDJoshiHCDevelopment of a novel nitro-derivative of noscapine for the potential treatment of drug-resistant ovarian cancer and T-cell lymphomaMol Pharmacol20066961801180916517755
- ZhouJGuptaKAggarwalSBrominated derivatives of noscapine are potent microtubule-interfering agents that perturb mitosis and inhibit cell proliferationMol Pharmacol200363479980712644580
- HawkinsMJSoon-ShiongPDesaiNProtein nanoparticles as drug carriers in clinical medicineAdv Drug Deliv Rev200860887688518423779
- GronebergDAGiersigMWelteTPisonUNanoparticle-based diagnosis and therapyCurr Drug Targets20067664364816787165
- BriggerIDubernetCCouvreurPNanoparticles in cancer therapy and diagnosisAdv Drug Deliv Rev200254563165112204596
- HungODrug transformation: Advances in drug delivery systemsCan J Anaesth200653111074107717079632
- JiangWKimBYRutkaJTChanWCAdvances and challenges of nanotechnology-based drug delivery systemsExpert Opin Drug Deliv20074662163317970665
- LazorthesYSallerin-CauteBVerdieJCBastideRAdvances in drug delivery systems and applications in neurosurgeryAdv Tech Stand Neurosurg1991181431921930373
- MoghimiSMHunterACMurrayJCLong-circulating and target-specific nanoparticles: theory to practicePharmacol Rev200153228331811356986
- TokudaYAntibodies as molecular target-based therapy: trastuzumabInt J Clin Oncol20038422422912955577
- ReddyKRControlled-release, pegylation, liposomal formulations: new mechanisms in the delivery of injectable drugsAnn Pharmacother2000347–891592310928404
- PortneyNGOzkanMNano-oncology: drug delivery, imaging, and sensingAnal Bioanal Chem2006384362063016440195
- WestJLHalasNJApplications of nanotechnology to biotechnology commentaryCurr Opin Biotechnol200011221521710753774
- VogelsonCAdvances in drug delivery systems2001 Available from: http://pubs.acs.org/subscribe/journals/mdd/v04/i04/html/MDD04FeatureVogelson.html
- WeberCKreuterJLangerKDesolvation process and surface characteristics of HSA-nanoparticlesInt J Pharm2000196219720010699717
- LinWCoombesAGDaviesMCDavisSSIllumLPreparation of sub-100 nm human serum albumin nanospheres using a pH-coacervation methodJ Drug Target1993132372438069565
- LinWGarnettMCDavisSSSchachtEFerrutiPIllumLPreparation and characterisation of rose Bengal-loaded surface-modified albumin nanoparticlesJ Control Release200171111712611245913
- MerodioMArnedoARenedoMJIracheJMGanciclovir-loaded albumin nanoparticles: characterization and in vitro release propertiesEur J Pharm Sci200112325125911113644
- YuanHMiaoJDuYZYouJHuFQZengSCellular uptake of solid lipid nanoparticles and cytotoxicity of encapsulated paclitaxel in A549 cancer cellsInt J Pharm20083481–213714517714896
- UenoNTYuDHungMCChemosensitization of HER-2/neu-overexpressing human breast cancer cells to paclitaxel (Taxol) by adenovirus type 5 E1AOncogene19971589539609285690
- KoziaraJMLockmanPRAllenDDMumperRJPaclitaxel nanoparticles for the potential treatment of brain tumorsJ Control Release200499225926915380635
- MüllerRHMaassenSWeyhersHMehnertWPhagocytic uptake and cytotoxicity of solid lipid nanoparticles (SLN) sterically stabilized with poloxamine 908 and poloxamer 407J Drug Target1996431611708959488
- RubinoOPKowalskyRSwarbrickJAlbumin microspheres as a drug delivery system: relation among turbidity ratio, degree of cross-linking, and drug releasePharm Res1993107105910658378248